Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology

Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD technical review based on the GRADE methodology

(2022) Stefanos Bonovas et al.   DIGESTIVE AND LIVER DISEASE

A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease

(2021) Adam S. Cheifetz et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

SPOSAB ABP 501 ‐ A Sicilian Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Adalimumab Biosimilar ABP 501

(2021) Fabio Salvatore Macaluso et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis

(2020) Joseph D. Feuerstein et al.   GASTROENTEROLOGY

The SPOSIB SB2 Sicilian Cohort: Safety and Effectiveness of Infliximab Biosimilar SB2 in Inflammatory Bowel Diseases, Including Multiple Switches

(2020) Fabio Salvatore Macaluso et al.   INFLAMMATORY BOWEL DISEASES

Comparative efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti-TNF agent: a multicentre cohort study

(2020) Marianne Hupé et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

A propensity score weighted comparison of Vedolizumab, Adalimumab, and Golimumab in patients with ulcerative colitis

(2020) Fabio Salvatore Macaluso et al.   DIGESTIVE AND LIVER DISEASE

Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohn’s disease: long-term outcomes for 11 928 patients in the UK inflammatory bowel disease bioresource

(2020) Evangelos Stournaras et al.   GUT

Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study

(2020) Daniela Pugliese et al.   United European Gastroenterology Journal

Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients with Inflammatory Bowel Diseases: a Systematic Review and Meta-analysis

(2019) Siddharth Singh et al.   Clinical Gastroenterology and Hepatology

Effectiveness and safety of Ustekinumab for the treatment of Crohn’s disease in real-life experiences: a meta-analysis of observational studies

(2019) Fabio Salvatore Macaluso et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium

(2018) Neeraj Narula et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Natural History of Adult Ulcerative Colitis in Population-based Cohorts: A Systematic Review

(2018) Mathurin Fumery et al.   Clinical Gastroenterology and Hepatology

Ustekinumab in the management of Crohn’s disease: Expert opinion

(2018) Alessandro Armuzzi et al.   DIGESTIVE AND LIVER DISEASE

The real-world effectiveness of vedolizumab on intestinal and articular outcomes in inflammatory bowel diseases

(2018) Fabio Salvatore Macaluso et al.   DIGESTIVE AND LIVER DISEASE

Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence

(2018) Maria Lia Scribano   WORLD JOURNAL OF GASTROENTEROLOGY

The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy

(2018) Alessandro Armuzzi et al.   INFLAMMATORY BOWEL DISEASES

Outcome in ulcerative colitis after switch from adalimumab/golimumab to infliximab: A multicenter retrospective study

(2018) Anna Viola et al.   DIGESTIVE AND LIVER DISEASE

Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis

(2017) Carlos Taxonera et al.   INFLAMMATORY BOWEL DISEASES

Ulcerative colitis

(2017) Ryan Ungaro et al.   LANCET

Discontinuation of Infliximab in Patients With Ulcerative Colitis Is Associated With Increased Risk of Relapse: A Multinational Retrospective Cohort Study

(2016) Gionata Fiorino et al.   Clinical Gastroenterology and Hepatology

The biologics of ulcerative colitis

(2016) Fabio Salvatore Macaluso et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed

(2015) J. P. Gisbert et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Outcomes of rescue therapy in acute severe ulcerative colitis: data from the United Kingdom inflammatory bowel disease audit

(2013) R. W. Lynch et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Adalimumab in active ulcerative colitis: A “real-life” observational study

(2013) Alessandro Armuzzi et al.   DIGESTIVE AND LIVER DISEASE

Successive Treatment With Cyclosporine and Infliximab in Steroid-Refractory Ulcerative Colitis

(2011) S Leblanc et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Delayed surgery for acute severe colitis is associated with increased risk of postoperative complications

(2010) J. Randall et al.   BRITISH JOURNAL OF SURGERY

The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in Inflammatory Bowel Disease☆

(2010) Ambrogio Orlando et al.   DIGESTIVE AND LIVER DISEASE

Going from evidence to recommendations

(2008) Gordon H Guyatt et al.   BMJ-British Medical Journal